1. Clinical Overview of Hexarelin

Molecule: Hexarelin (Examorelin) is a synthetic growth hormone-releasing peptide (GHRP) that potently stimulates endogenous GH secretion via ghrelin receptor (GHS-R1a) agonism.

Classification: Growth Hormone Secretagogue (GHS) · Synthetic hexapeptide · Ghrelin receptor (GHS-R1a) agonist · Anabolic and cardioprotective peptide

Clinical Significance

Potent GH-releasing effects, stronger than GHRP-2 and GHRP-6
Indirect increase in IGF-1 production
Anti-catabolic, pro-anabolic effects on lean mass
Cardioprotective potential in preclinical and early human data

2. Mechanisms of Action

2.1 Pituitary GH Release

Strong binding to GHS-R1a in anterior pituitary
Amplifies endogenous pulsatile GH secretion
Stimulates hepatic IGF-1 synthesis

2.2 Ghrelin-Mimetic Effects

Promotes appetite and nutrient partitioning
Enhances mitochondrial metabolism
Supports muscle regeneration and recovery

2.3 Cardiac Receptor Activation

GHS-R1a receptors in myocardium
Improves left ventricular function in heart failure models
Reduces myocardial fibrosis and apoptosis

2.4 Anabolic & Anti-Catabolic Activity

Increases lean body mass
Decreases visceral adiposity
May protect against glucocorticoid-induced catabolism

3. Evidence Summary — Clinical Domains

3.1 Anabolic Support & Muscle Wasting

Promotes GH/IGF-1 axis activation, muscle hypertrophy, and improved nitrogen retention. Investigated for cachexia, sarcopenia, and age-related muscle loss.

3.2 Performance & Recovery

Enhanced muscle repair post-exercise, reduces exercise-induced breakdown, may improve strength and endurance via GH/IGF-1.

3.3 Cardiac Function & Heart Failure Models

Improves LVEF, reduces fibrosis in heart failure models. Human pilot trials show improved cardiac biomarkers.

3.4 Fat Loss & Metabolic Shift

Mild lipolytic effects via GH pathway. May improve insulin sensitivity over time. Reduction in visceral adiposity noted in some trials.

4. Clinical Protocols

4.1 Administration Route

Subcutaneous injection preferred (1–2× daily). IM optional.

4.2 Reconstitution

2 mg lyophilized vial · Reconstitute with 2 mL bacteriostatic saline · Final concentration: 1 mg/mL

4.3 Dosing Protocols

Standard Regenerative: 100 mcg × 2/day (AM and PM) · 8–12 weeks
Performance/Anabolic: 200 mcg × 2/day (fasted AM and pre-bed) · 6–10 weeks
Cardiac Support (Research): 100 mcg daily × 10–12 weeks · Evaluate LV function, BNP, troponins
Anti-Catabolic: 100–200 mcg once daily in chronic illness or corticosteroid use

5. Clinical Integration Strategies

5.1 Hexarelin + CJC-1295 (No DAC)

Synergistic GH-releasing stack. Pulsatile GH + GHRH enhancement.

5.2 Hexarelin + BPC-157 or TB-500

Musculoskeletal recovery synergy. Supports tendon, ligament, and muscle regeneration.

5.3 Hexarelin + MOTS-c or SS-31

Mitochondrial health during anabolic phase. Offsets fatigue, supports cardiovascular tissue.

5.4 Hexarelin + 5-Amino-1MQ

Metabolic recomposition synergy. Lean mass gain + NNMT modulation.

6. Decision Tree for Clinical Research Use

Primary Goal

Goal	Hexarelin Use
Muscle gain	Yes, moderate-high dose
Cardiac remodeling	Consider, low dose
GH stimulation (pulsatile)	Ideal candidate
Anti-catabolic support	Strong consideration
Pediatric GH deficiency	Not recommended (use GH therapy)

Contraindication or Caution Needed

Condition	Consideration
Active malignancy	Use caution (GH/IGF-1 axis)
Diabetes	Monitor glucose (transient insulin resistance)
Pregnancy	Contraindicated

7. Safety, Side Effects & Monitoring

7.1 Side Effects (Generally Mild)

Hunger
Injection site irritation
Water retention (mild)
Transient prolactin increase
Numbness/tingling (rare)

7.2 Contraindications

Active malignancy
Pregnancy/lactation
Uncontrolled diabetes or retinopathy

7.3 Monitoring

IGF-1 levels (baseline and 6–8 weeks)
Fasting glucose (optional)
Prolactin (if symptomatic)
Cardiac markers if used in CHF context

Legal Disclaimer

The information contained in this document is provided solely for educational and informational purposes for licensed healthcare professionals. It is not intended as medical advice, does not establish a standard of care, and must not be interpreted as instructions for the diagnosis, treatment, cure, mitigation, or prevention of any disease.

Hexarelin, and other peptides referenced herein are not FDA-approved drugs. Their clinical use may constitute off-label or investigational use.

Peptide Protocol Portal, its affiliates, authors, and contributors make no representations or warranties, express or implied, regarding the accuracy, completeness, safety, or regulatory compliance of the information presented.

By using this document, the reader agrees that Peptide Protocol Portal, its parent company, subsidiaries, employees, agents, and advisors shall not be held liable for any damages, injuries, regulatory actions, or adverse outcomes arising from the application, misapplication, or interpretation of the information contained herein.

Use at your own risk. Consult all relevant laws, regulations, and professional guidelines before implementing any protocols described in this document.

References — Hexarelin Clinical Reference Guide

1. Garcia, J. M., et al. (1997). Effects of hexarelin on growth hormone secretion and body composition. Journal of Clinical Endocrinology & Metabolism, 82(2), 296–301.

2. Smith, R. G., et al. (2000). Ghrelin and growth hormone secretagogues: a new era of endocrine regulation. Trends in Endocrinology & Metabolism, 11(3), 118–123.

3. Locatelli, V., et al. (2002). Hexarelin protects the heart against ischemia/reperfusion injury through growth hormone-independent mechanisms. Endocrinology, 143(12), 4681–4689.

4. Rossoni, G., et al. (2009). Hexarelin-induced cardioprotection: role of nitric oxide and PI3K/Akt signaling. Cardiovascular Research, 83(2), 303–312.

5. Nass, R., et al. (2008). Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults. Annals of Internal Medicine, 149(9), 601–608.

6. Nagaya, N., et al. (2004). Ghrelin improves left ventricular dysfunction and attenuates development of cardiac cachexia in patients with chronic heart failure. Circulation, 110(24), 3674–3679.